Paradigm Biopharmaceuticals Limited
PBIGF
$0.2083
$0.00633.12%
OTC PK
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -21.05% | -23.08% | -- |
| Gross Profit | -- | -- | 44.44% | 45.45% | -- |
| SG&A Expenses | -37.50% | -36.05% | 25.22% | 22.13% | -25.62% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -87.31% | -87.01% | -45.97% | -47.30% | 51.67% |
| Operating Income | 87.34% | 87.05% | 45.97% | 47.31% | -51.69% |
| Income Before Tax | 88.16% | 87.88% | 52.28% | 53.46% | -55.54% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 88.16% | 87.88% | 52.28% | 53.46% | -55.54% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 88.16% | 87.88% | 52.28% | 53.46% | -55.54% |
| EBIT | 87.34% | 87.05% | 45.97% | 47.31% | -51.69% |
| EBITDA | 87.47% | 87.17% | 46.09% | 47.42% | -51.83% |
| EPS Basic | 89.89% | 89.74% | 61.86% | 62.63% | -39.85% |
| Normalized Basic EPS | 90.00% | 89.74% | 61.54% | 62.90% | -39.34% |
| EPS Diluted | 89.89% | 89.74% | 64.42% | 65.20% | -39.85% |
| Normalized Diluted EPS | 90.00% | 89.74% | 61.54% | 62.90% | -39.34% |
| Average Basic Shares Outstanding | 18.10% | 18.10% | 24.52% | 24.52% | 11.36% |
| Average Diluted Shares Outstanding | 18.10% | 18.10% | 24.52% | 24.52% | 11.36% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |